NM_005529.7:c.10721-305C>T
Variant names: 
Variant summary
Our verdict is Benign. The variant received -14 ACMG points: 0P and 14B. BP4_StrongBP6_ModerateBA1
The NM_005529.7(HSPG2):c.10721-305C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.242 in 152,132 control chromosomes in the GnomAD database, including 4,446 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★).
Frequency
 Genomes: 𝑓 0.24   (  4446   hom.,  cov: 32) 
Consequence
 HSPG2
NM_005529.7 intron
NM_005529.7 intron
Scores
 2
Clinical Significance
Conservation
 PhyloP100:  -1.04  
Publications
14 publications found 
Genes affected
 HSPG2  (HGNC:5273):  (heparan sulfate proteoglycan 2) This gene encodes the perlecan protein, which consists of a core protein to which three long chains of glycosaminoglycans (heparan sulfate or chondroitin sulfate) are attached. The perlecan protein is a large multidomain proteoglycan that binds to and cross-links many extracellular matrix components and cell-surface molecules. It has been shown that this protein interacts with laminin, prolargin, collagen type IV, FGFBP1, FBLN2, FGF7 and transthyretin, etc., and it plays essential roles in multiple biological activities. Perlecan is a key component of the vascular extracellular matrix, where it helps to maintain the endothelial barrier function. It is a potent inhibitor of smooth muscle cell proliferation and is thus thought to help maintain vascular homeostasis. It can also promote growth factor (e.g., FGF2) activity and thus stimulate endothelial growth and re-generation. It is a major component of basement membranes, where it is involved in the stabilization of other molecules as well as being involved with glomerular permeability to macromolecules and cell adhesion. Mutations in this gene cause Schwartz-Jampel syndrome type 1, Silverman-Handmaker type of dyssegmental dysplasia, and tardive dyskinesia. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2014] 
HSPG2 Gene-Disease associations (from GenCC):
- Schwartz-Jampel syndrome type 1Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), G2P
- Silverman-Handmaker type dyssegmental dysplasiaInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, ClinGen, Labcorp Genetics (formerly Invitae)
- Schwartz-Jampel syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -14 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.91). 
BP6
Variant 1-21834230-G-A is Benign according to our data. Variant chr1-21834230-G-A is described in ClinVar as Benign. ClinVar VariationId is 1257676.Status of the report is criteria_provided_single_submitter, 1 stars. 
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.375  is higher than 0.05. 
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  0.241  AC: 36706AN: 152014Hom.:  4440  Cov.: 32 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
36706
AN: 
152014
Hom.: 
Cov.: 
32
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome  0.242  AC: 36745AN: 152132Hom.:  4446  Cov.: 32 AF XY:  0.240  AC XY: 17849AN XY: 74378 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
36745
AN: 
152132
Hom.: 
Cov.: 
32
 AF XY: 
AC XY: 
17849
AN XY: 
74378
show subpopulations 
African (AFR) 
 AF: 
AC: 
9510
AN: 
41506
American (AMR) 
 AF: 
AC: 
2976
AN: 
15288
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
854
AN: 
3470
East Asian (EAS) 
 AF: 
AC: 
869
AN: 
5164
South Asian (SAS) 
 AF: 
AC: 
1879
AN: 
4820
European-Finnish (FIN) 
 AF: 
AC: 
2897
AN: 
10588
Middle Eastern (MID) 
 AF: 
AC: 
49
AN: 
294
European-Non Finnish (NFE) 
 AF: 
AC: 
16970
AN: 
67984
Other (OTH) 
 AF: 
AC: 
518
AN: 
2110
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.502 
Heterozygous variant carriers
 0 
 1426 
 2853 
 4279 
 5706 
 7132 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
 0 
 392 
 784 
 1176 
 1568 
 1960 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
Asia WGS 
 AF: 
AC: 
1004
AN: 
3478
ClinVar
Significance: Benign 
Submissions summary: Benign:1 
Revision: criteria provided, single submitter
LINK: link 
Submissions by phenotype
not provided    Benign:1 
Apr 04, 2019
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.